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Abstract
Background: Pleomorphic carcinoma is a rare primary lung carcinoma that occurs at a rate of about 0.3%. Even
with complete resection, the tumor usually recurs aggressively, resulting in a poor prognosis. Herein, we report a
case of advanced pleomorphic carcinoma of the lung who had a long survival time after resection of the primary
and metastatic sites.
Case presentation: A 48-year-old man was admitted to our hospital due to abdominal pain. Systemic examination
revealed a lung mass on the right and a tumor in the jejunum. Surgical resection of both tumors revealed
pleomorphic carcinoma of the lung with metastasis to the jejunum. Follow-up after 6 years showed that the
patient remained recurrence-free, without the need for additional postoperative treatment.
Conclusions: A vigorous treatment strategy that included surgery had the potential to offer long-term survival,
despite an advanced pleomorphic carcinoma with distant metastasis to other organs. Reports on more similar cases
are needed to evaluate the value of this treatment option.
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Background
The mainstream treatment strategy for advanced non-small
cell lung cancer (NSCLC) is systemic chemotherapy. Sur-
gery or radiotherapy is usually employed for cases with
early stage and for the purpose of reducing local symptoms
caused by the tumor. On the other hand, pleomorphic car-
cinoma is a rare tumor that consists approximately 0.3% of
primary lung tumors. It is aggressive and recurrence is
common even after complete resection in the early stage.
In this report, we described a case of a patient with ad-
vanced pleomorphic carcinoma of the lung and who sur-
vived for a long time after resection of the primary and
metastatic sites.
Case presentation
A 48-year-old man was admitted to our hospital due to
pain and tenderness in the upper and central part of the
abdomen when fasting. There were no pertinent
symptoms. His past medical history included benign
prostate hyperplasia. He was a current smoker for 42
pack-years. Physical examination revealed nothing sig-
nificant except for tenderness in the upper and central
part of the abdomen.
Abdominal computed tomography (CT), upper gastro-
intestinal endoscopy, and complete colonoscopy revealed
no abnormality. However, chest X-ray revealed a massive
shadow in the right upper lung field (Fig. 1a), which was
confirmed by chest CT showing a 65-mm mass in the right
upper lobe with chest wall invasion (Fig. 1b). 18F-Fluoro-
deoxyglucose (FDG) positron emission tomography-CT
showed abnormal accumulation of FDG in the lung tumor,
as well as in a portion of the jejunum. Intestinal fluoroscopy
revealed stenosis without obstruction in the distal part of
the jejunum (Fig. 2). There was no evidence of lymph node
involvement and distant metastases other than the jejunum.
The clinical diagnosis was right lung cancer with metastasis
to the jejunum. Transbronchial lung biopsy revealed
no evidence of malignancy. The laboratory data re-
vealed slight elevation in gamma GTP (80 IU/L) and
C-reactive protein (0.78 mg/dL). The levels of tumor
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markers like carcinoembryonic antigen, cytokeratin-19
fragments, and pro-gastrin-releasing peptide were not
elevated. Because the metastatic tumor in the jejunum
was symptomatic and was localized in a single organ,
surgery was planned for both the primary and meta-
static sites. Partial resection of the jejunum was per-
formed initially, followed by right upper lobectomy
with chest wall resection within a month. The patient
had an uncomplicated postoperative course.
Pathologic analysis of the lung tumor revealed atypical
spindle cells with irregular and hyperchromatic nuclei
invasively proliferating and arranged in interlacing pat-
terns (Fig. 3a). Epithelioid cells with tubular differenti-
ation (components of adenocarcinoma) were also noted
in a small part of the lung specimen (Fig. 3b). Immuno-
histochemical studies revealed that the tumor cells were
positive for vimentin, AE1/AE3, and TTF-1 but negative
for c-Kit, alpha SMA, S-100, and CD34. The pathologic
diagnosis was pleomorphic carcinoma of the lung
(Fig. 3a, b). The tumor in the jejunum was similar in
both morphologic and immunohistochemical analyses,
confirming a metastasis from the pleomorphic carcin-
oma of the lung (Fig. 3c).
Since the patient did not want to receive adjuvant
chemotherapy, we advised careful observation. The pa-
tient remained alive without recurrence for 6 years.
Discussion
Pleomorphic carcinoma is one of the subtypes of sarco-
matoid carcinoma among the four other subgroups, in-
cluding spindle cell carcinoma, giant cell carcinoma,
carcinosarcoma, and pulmonary blastoma. It is defined
as a poorly differentiated NSCLC (squamous cell carcin-
oma, adenocarcinoma, or large cell carcinoma) contain-
ing spindle cells and/or giant cells, or a carcinoma that
comprises spindle or giant cells alone, in at least 10% of
the tumor [1]. Pleomorphic carcinoma occurs in only
0.1–0.4% of all lung carcinomas and generally has a
more aggressive clinical course than the other types of
NSCLC. According to the Japanese Joint Committee of
Lung Cancer Registry data, its 5-year overall survival
was 20–40%, whereas that of the other histologic types
was 61.4% [1–4]. For such aggressive cancers, multimod-
ality therapy needs to be considered, but the optimal
treatment strategy remains undefined because of its rar-
ity. The effective regimen for pleomorphic carcinoma,
which is often diagnosed in the advanced stage, is not
Fig. 1 Radiologic imaging of the chest of a 48-year-old man with pleomorphic carcinoma of the lung. a Chest radiograph reveals a 6-cm shadow
in the right upper lung field. b Chest computed tomography reveals a 6.5-cm tumor in the right upper lobe with invasion to the chest wall
Fig. 2 Intestinal fluoroscopy in a 48-year-old man with pleomorphic
carcinoma of the lung. Stenosis in the distal part of the jejunum is
shown (arrows)
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well established at the moment; in addition, adjuvant
chemotherapy does not appear helpful.
Massive coagulation necrosis and lymph node metas-
tases were identified as prognostic factors for a poorer
outcome of pleomorphic carcinomas [2, 3]. However,
pleomorphic carcinoma with pN0 has poorer prognosis
than other variants of NSCLC with pN0 [3]. Frequent
vascular invasion is the cause of this unfavorable prog-
nosis, even in early-stage disease.
Some reports showed that a vigorous treatment strategy
that included surgery had the potential to offer long-term
survival, despite an advanced pleomorphic carcinoma with
distant metastasis to other organs. In NSCLC, careful pa-
tient selection for complete resection of both primary and
metastatic sites can result in a favorable outcome. Hasumi
et al. reported on 35 surgically resected NSCLC with oli-
gometastasis and concluded that patients without lymph
node metastases had long-term survival [5]. For pleo-
morphic carcinoma, Aokage et al. reported two patients
who survived for over 4 years after resection of the pri-
mary site and the gastric metastasis [6] and Yamanashi et
al. reported a patient with brain metastasis who was suc-
cessfully treated by brain metastasectomy followed by
chemotherapy and resection of the primary lesion [7].
Similar to our present case, these reported pleomorphic
carcinoma patients did not have regional lymph node me-
tastases by both clinical and pathologic diagnoses. It is im-
portant to note that this unexpectedly good outcome
should not become a rationale for surgical metastasect-
omy in all cases. However, complete primary lung tumor
resection with metastasectomy might be a treatment op-
tion for pleomorphic carcinoma in node-negative patients.
Conclusions
We reported a rare case of advanced pleomorphic lung
carcinoma with metastasis to the jejunum who was suc-
cessfully treated by surgery alone. Node-negative pa-
tients with oligometastasis might be candidates for
surgery. Reports on more similar cases are needed to
evaluate the value of this treatment option.
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lung and c the jejunum shows atypical spindle cells with irregular and hyperchromatic nuclei with invasive proliferation and interlacing patterns
of arrangement. b Epithelioid cells with tubular differentiation were also noted in the lung specimen (stained with hematoxylin and eosin, ×400)
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